INDEX

Note: page numbers followed by f and t represent figures and tables respectively.

Ablative procedures
in laser skin resurfacing, 159
for Meniere’s disease, 253–254, 257, 261
radiofrequency, of soft palate, for snoring, 60
Acoustic neuroma, intracanalicular. See Intracanalicular acoustic neuroma
Acute facial palsy/paralysis, 218–230. See also Bell’s palsy
evaluation and management, 219–221, 224–225
algorithm for, 224t
in exceptional cases, 225
traumatic, 228–230
Acute otitis media, 401–402
differential diagnosis, 411, 411t
treatment options for, 401–402, 412–414, 412t–414t
in recurrent form, 415, 415t
Adenoidectomy, for pediatric chronic rhinosinusitis, 359, 362, 371
Adjuvant chemotherapy, in HNSCC treatment, 44
advanced resectable disease, 50–51
Adjuvant therapy
chemotherapy. See Adjuvant chemotherapy
for negative neck, indications for, 4
for parotid neoplasm, 346–347, 351
Aerodigestive tract, upper cancer of. See Unknown primary with neck disease
fistulae formation during surgery in, 307–319
Age
otosclerosis management and, 233
pediatric cochlear implantation and, 425
post-tympanostomy otorrhea and, 196
sleep apnea and, 57
SMAS surgery and, 140
tympanoplasty and, 216–217
Aging, reconstructive surgery outcomes and, 75–76
Air-bone gap, stapedectomy and, 234
Aircrew, otosclerosis management in, 234
Antibiotic therapy
for acute otitis media, 412–413, 412t
recurrent form, 415
for otitis media with effusion, 414–415, 1414t
persistent, 413–414
susceptibility, 411–412, 412t
for pediatric chronic rhinosinusitis, 359, 362, 369, 370t
in tympanostomy tube insertion in postoperative period, 199
as prophylaxis, topical and systemic, 198
Antihistamines, for pediatric chronic rhinosinusitis, 362
Antral lavage, for pediatric chronic rhinosinusitis, 371
Auricular cartilage grafts, autologous, 176, 183, 190
Autologous grafts, in rhinoplasty
advantages and disadvantages, 174t
auroplastic. See Auroplastic implants
hearing status in postoperative period, 377t
unilateral congenital. See Unilateral atretic ear
Audiogram, in perilymph fistulae diagnosis, 304
Audiometry
in intracanalicular acoustic neuroma evaluation, 276
during stapedectomy, 235
Auditory brainstem response audiometry, in intracanalicular acoustic neuroma evaluation, 276
Auditory neuropathy, cochlear implants
in child with, 431
Augmentation materials, for implants, 175t
advantages and disadvantages, 182t
auroplastic. See Auroplastic implants
autologous. See Autologous grafts
heterologous, 184–185
Aural atresia
bilateral congenital, 381
hearing status in postoperative period, 377t
unilateral congenital. See Unilateral atretic ear
Aural atresia repair, for unilateral atretic ear, 384
Atretic ear, unilateral. See Unilateral atretic ear
Augmentation materials, for implants, 175t
Auricular cartilage grafts, autologous, 176, 183, 190

463
Bell’s palsy, 219–221
clinical course, 228
facts about, 223
treatment, 228
adequate, results of, 223–224
inadequate, results of, 224
Benign paroxysmal positional nystagmus, perilymph fistulae and, 295–296
Bilateral aural atresia, 381
Biopsy. See Fine-needle aspiration biopsy
Biplane facelift opportunistic, 149
technique, 150–154
Bleomycin, for HNSCC, 40
Bone cartilage grafts, autologous, 176, 184
Bottle-feeding, post-tympanostomy otorrhea and, 197
Branchial arch syndrome, 397
Caldwell-Luc procedure, for pediatric chronic rhinosinusitis, 371
Canal wall-down approach, in cholesteatoma management, 208
clinical and surgical pitfalls, 210–212
factors affecting choice of, 209, 210t
for recurrent chronic otitis media, 211f
Canal wall-up approach, in cholesteatoma management, 208
clinical and surgical pitfalls, 210–212
factors affecting choice of, 209, 210t
for recurrent chronic otitis media, 211f
Carboplatin, for HNSCC, 34, 40
Carotid angiography, in jugular foramen tumor evaluation bilateral, 441
findings, 452t
Cartilage grafts, in rhinoplasty autologous, 175–176, 183–184
heterologous, 184–185
homologous, 176–177, 184
Catecholamine screening, in jugular foramen tumor management, 441
Cephalometry, in uvulopalatopharyngoplasty candidates, 57–58
sleep apnea evaluation and, 59
Cerebellopontine surgery, acute facial paralysis following, 219
Cheek fat, SMAS surgery and, 140
Chemical peels, 160, 164–169. See also Phenol peels; Trichloroacetic acid peels agents for, 160
classification, 165t
background to, 163
limitations, 160–161
Chemoprevention, of nonsquamous cancer, 52–53
Chemotherapy for HNSCC adjuvant. See Adjuvant chemotherapy in advanced resectable disease, 49–52
agents used in, 39
concomitant. See Concomitant chemo/radiotherapy, for HNSCC
induction type, 36, 41–42
in advanced resectable disease, 49–50
in locally advanced disease, 36
intra-arterial. See Intra-arterial chemotherapy, for HNSCC
in locally advanced disease, with radiotherapy, 36, 37
neoadjuvant, 41–42
palliative, 39–41
with radiotherapy, 41
in recurrent/metastatic disease, 49
combination, 35, 35t, 39–41
drug-agent, 34–35, 34t, 35t, 39–40
for parotid neoplasm, 346
prior to reconstructive surgery, 77
Children aural atresia in. See Unilateral atretic ear
chronic rhinosinusitis in. See Pediatric chronic rhinosinusitis congenitally deaf, cochlear implants in. See Congenitally deaf children, cochlear implants in sinusitis in. See Pediatric sinusitis
Chin prosis, SMAS surgery and, 140
Cholesteatoma chronic otitis media and, 208–209, 208t, 209f, 210f
surgical management, 203–217
aims and objectives, 214
decision-making in, 215–216
goals, 204t
intraoperative monitoring, 206
ossicular reconstruction, 206
patient counseling in, 214–215
preoperative imaging in, 204–205
risks and complications, 216
techniques, 208, 209–212, 210t, 211f, 214
open versus closed cavity, 205–206, 205t, 206t
Chronic otitis media categories, 208, 208t
with cholesteatoma, management of. See Cholesteatoma, management
initial evaluation, 208
management algorithms for primary form, 208–209, 209f
recurrent form, 209, 210f
Chronic rhinosinusitis in children. See Pediatric chronic rhinosinusitis postoperative outcomes. See Sinus surgery, outcomes in
Chronic sinusitis, 92
postoperative outcomes. See Sinus surgery, outcomes in
Chronic Sinusitis Survey, 85, 86, 88, 89f, 96, 96t
application, 96–97
sinusitis health status outcomes, 97–98f
Chronic Sinusitis TyPE Specific Questionnaire, 85, 86, 88, 96t
Chylous fistulae, 313
Ciliary dyskinesia, 91–92
Cisplatin, for HNSCC, 34, 40
Clarion cochlear implant system, 424
Clariion cochlear implant system, 424
Cleft palate, post-tympanostomy otorrhea and, 196
Clinical observation of negative neck, 2
elective neck dissection versus, 7–8
with serial imaging, for intracanalicular acoustic neuroma, 268
Closed-head trauma, facial paralysis due to, 228–229
decision algorithms, 229t
Cochlear implant systems, 422–423
Clarion, 424
Med-El, 424
Nucleus, 424
Cochlear implants in congenitally deaf children. See Congenitally deaf children, cochlear implants in
Index

465

Deaf culture and, 430–431
historical perspective, 418, 429
opposition to, 418
Collagen, contraction versus
compaction, laser skin
resurfacing and, 159
Colonic segments, for free flaps, 68
Color Doppler sonography, parotid
neoplasm, 350
Combat pilots, otosclerosis
management in, 234
Combined-modality therapy, for
HNSCC, 41
Comorbidity
perilymph fistulae and, 295–296
post-tympanostomy otorrhea and,
196
Compliance, with postoperative laser
skin resurfacing regimen, 159
Computed tomography
determining need for elective neck
dissection, 6
jugular foramen tumors, 452t
for diagnosis, 459–460
of negative neck, 2
parotid neoplasm, 341, 344–345, 349
in pediatric rhinosinusitis diagnosis, 367
in preoperative cholesteatoma
evaluation, 204–205
for staging chronic rhinosinusitis, 86, 87t, 94, 95t
temporal bone malignancies, 280
in unilateral atretic ear evaluation, 379, 381
high-resolution CT, 382–383, 384
unknown primary with neck disease, 323, 329, 330, 335–336
Conchal cartilage grafts, autologous, 175–176
Concomitant chemo/radiotherapy, for
HNSCC, 42, 44
in advanced resectable disease, 51–52
palliative, 39–40
randomized trials, 43t
in recurrent/metastatic disease, 35, 35t
singlet agents versus, 40–41
Congenitally deaf children, cochlear
implants in, 417–433
age at implantation, 425, 429–430
arguments against use of, 418–419
child’s perceptions and, 431
defaf culture and, 430–431
ethical opposition to, 419–420
family and educational support for,
430
versus hearing aid benefit, 430
implant systems for, 422–423
multiply disabled and/or with
auditory neuropathy, 431
neural and cortical
plasticity/reorganization, 432
outcome data, 431–432
patient selection criteria, 422
results of implantation, 424–425
demographic influences on, 425
surgical technique and
considerations, 423–424
Continuous positive airway pressure
for retrognathic patient, 391, 397
for sleep apnea, 57
in uvulopalatopharyngoplasty
candidates, 59–60, 63–64
Cortical plasticity/reorganization,
cochlear implants and, 432
Cosmetic procedures, for paralyzed face
rehabilitation, 129t, 132.
See also Facelift(s)
Costal cartilage grafts, autologous, 183–184
Counseling, tympanoplasty patient,
214–215
CPAP. See Continuous positive airway
pressure
Craniofacial resection, for inverted
papilloma
CSS. See Chronic Sinusitis Survey
CT. See Computed tomography
Cutaneous free flaps, 68
CWD. See Canal wall down approach
CWU. See Canal wall up approach
Day care, post-tympanostomy otorrhea
and, 197
Deaf culture, and cochlear implants,
430–431
Deafferentation procedures, for
Meniere’s disease, 254, 257
Deafness, pediatric congenital, cochlear
implants in. See Congenitally
deaf children, cochlear
implants in
Debridement, after sinus surgery,
outcome in. See Sinus surgery,
outcome in
Decongestants, for pediatric chronic
rhinosinusitis, 362, 370
Deep-plane dissection, in biplane
facelift, 152–153
Deep-plane rhytidectomy
background to, 142–143
indications and contraindications
for, 146
SMAS surgery versus, 137–155
technique, 143–144
tuck rates in, 145, 145t
Degloving, mid-facial, for inverting
papilloma management, 30
Deltopectoral flap, 68
Depigmentation, after phenol peels, 169
Dermabrasion, mechanical, 160
limitations, 160–161
Dermatitis, external ear canal, post-
tympanostomy otorrhea and,
196
Destructive procedures, for Meniere’s
disease, 253–254, 257, 261
Disabled child, cochlear implants in,
431
Dissection techniques
in biplane facelift
deep-plane, 152–153
lower face, 151–152
temple, 151
in craniofacial approach to jugular
foramen tumors, 442
in negative neck. See Elective neck
dissection
Diuretics, for Meniere’s disease, 252, 256–257
Dizziness, following tympanoplasty, 216
Docetaxel (Taxotere), for HNSCC, 34
Draining pressure equalization tubes
antibiotic use with
postoperatively, 199
pre- and intraoperatively, 198
complication. See Post-tympanostomy
otorrhea
granulation tissue and, 200
management, 191–202
acute, 192, 193t
chronic, 192–193, 193t
intraoperative findings, 197
patient factors in, 196–197
postoperative, 198–200
surgical approaches and techniques,
197–198
Draining pressure equalization tubes (continued)
materials for, 198
recommendations to patients with, 195
removal, 200
swimming and, 200
Dynamic procedures, for paralyzed face rehabilitation, 129t, 130–132.
See also Muscle transposition; Neural reinnervation procedures
advantages and disadvantages, 126t
background to, 134
as early intervention, 136
microneurovascular free tissue transfer, 129t, 131–132, 134
Dyskinesia, ciliary, 91–92
Ear
unilateral atretic. See Unilateral atretic ear
vent tube placement in. See Draining pressure equalization tubes
Ear canal, post-tympanostomy otorrhea and
antiseptic preparation and, 197
dermatitis in, 196
Ear infection, following tympanoplasty, 216
Ectropion of lower eyelid, after phenol peels, 169
Educational support, for cochlear implants in congenitally deaf children, 430
Elderly patients, reconstructive surgery in, 75–76
Elective neck dissection, for negative neck, 1–19
adjuvant therapy and, 4
clinical observation versus, 7–8
metastasis management in, 16, 16t
need for, 14–15, 14f
imaging studies determining, 6–7
patient selection for, 7, 15–16, 15t
potential effects of, 3
quality-of-life issues and, 110
radiation following, 11
sentinel node biopsy versus, 7
surgical extent in, 4
therapeutic neck dissection versus, 3, 4f, 7–8
tumor site and, 7
Elective neck irradiation, 2, 16
quality-of-life issues and, 110
Electrocochleography, in perilymph fistulae diagnosis, 304
Electroneuronography, in acute facial paralysis evaluation, 220, 227
Embolization, glomus jugulare tumor management, 441
Endolymphatic sac surgery, for Meniere’s disease, 253, 257, 261
Endoscopic surgery for inverting papilloma, 22–23, 25, 26–27, 30
medial maxillectomy, 26–27, 26f, 30
sinuses in children. See Functional endoscopic sinus surgery; Pediatric endoscopic sinus surgery
revision surgery and, 89
Endoscopy
in unknown primary with neck disease, 324
Endotracheal intubation, in retrognathic patient, 397
Environment, chronic rhinosinusitis and, 368–369
Epstein-Barr virus testing, in unknown primary with neck disease, 329, 330–331
Erythema after laser skin resurfacing, 172
after phenol peels, 168
Ethical issues, cochlear implants in congenitally deaf children, 430
Facial nerve in aural atresia surgery, 383, 387
monitoring during tympanoplasty, 216
and parotid neoplasm management, 350–351
monitoring, 345
traumatized, surgical repair of, 230
Facial palsy/paralysis. See Paralyzed face, rehabilitation
Facial reanimation. See Paralyzed face, rehabilitation
Facial symmetry, restoration, 134
Fat autologous, in rhinoplasty, 190
SMAS surgery and, 140
FESS. See Functional endoscopic sinus surgery
Fetal alcohol syndrome, 394
Fiberoptic endoscopy with Muller’s maneuver, in uvulopalatopharyngoplasty candidates, 59
Fibular osteocutaneous flaps, 74
Fine-needle aspiration biopsy determining need for elective neck dissection, 6
parotid neoplasm, 340, 344–345
sensitivity and specificity, 348t
Fire hazard, during laser skin resurfacing, 158
Fisch classification, glomus jugulare tumors, 438t
Fisch staging
jugular schwannomas, 455, 455t
temporal parangangiomas, 451, 451t
Fisch surgical approaches, to jugular
foramen tumors, 454t
Fistula test, perilymph fistulae and, 304
Fistulae
perilymph. See Perilymph fistulae
postoperative, 307–319
chylous, 313
diagnosis, 317
factors causing, 315–316
orocutaneous, 312–313
pharyngocutaneous, 312
planned, 317
prevention and optimization, 316–317
salivary, 307–311
treatment options, 317–318
Fitzpatrick classification, skin type,
159t, 164t
Fluoride (Fluorical), use in otosclerosis
management, 236
Footplate fenestra, in stapedectomy, 235
Free flaps
for head and neck reconstruction,
66–83. See also Reconstructive
surgery
advantages, 79
cost-effectiveness, 76
disadvantages, 79–80
donor sites, 67–70
in elderly patients, 75–76
future directions, 77
historical background to, 67
neck dissection and, 77
radiotherapy prior to, 76–77
selection, 73–75
tasks suited to, 80–82
unresolved issues in use of, 80
vascularized muscle, for facial
reanimation, 129t, 131–132
Free jejunal autografts, 68
Frozen section, in parotid neoplasm
diagnosis, 345
5-FU, for HNSCC, 34, 40
Functional endoscopic sinus surgery,
91, 93
for pediatric chronic rhinosinusitis,
363, 371–372
Fungal sinusitis, invasive, 92
GAHM (genioglossus advancement
with hyoid myotomy), 63
Gastric pull-up, 68
contraindications, 74
Gastroesophageal reflux
chronic rhinosinusitis and, 369
chronic sinusitis and, 358, 361–362
Genetic disorders, chronic
rhinosinusitis and, 368
Genioglossus advancement with hyoid
myotomy, 63
Gentamicin, use in Meniere’s disease,
257, 261
GER. See Gastroesophageal reflux
Glasscock-Jackson classification, glomus
jugulare tumors, 438t
Glogau classification, skin type, 165t
Glomus jugulare tumors
biology, 439
classification systems, 438–439, 438t
clinical presentation, 440
historical perspective, 438
radiotherapy for, 446
surgical approaches to, 442t
Glomus tympanicum tumors, surgical
approaches to, 442t
Glosopexy, in retrognathic patient, 390
with Pierre Robin sequence, 395
Glottic cancer, elective neck dissection
for, 7
Goldenhar syndrome, 397
Gore-Tex implants
in paralyzed face rehabilitation,
124–125, 132
advantages and disadvantages,
125–126, 126t
benefits, 125
technique, 125
in rhinoplasty, experience with, 189
Gracilis flap, for paralyzed face
rehabilitation, 132
Grafts
as alternatives to implants, 190
autologous. See Autologous grafts
defined, 187
heterologous, 184–185
homologous. See Homologous grafts
literature review, 187–188
otosclerosis management and, 235
Gratulation tissue, following
rhinoplasty tube insertion,
200
Harvard staging system, chronic
rhinosinusitis, 94, 95t
Head and neck squamous cell
carcinoma
chemotherapy for, 33–55. See also
Chemotherapy
elective neck dissection for. See
Elective neck dissection
evaluation of therapy for, 116–117
metastases in, 3, 3t
management, 15, 15t
quality of life for patients with.
See Quality of life
assessment instruments.
See Quality-of-life measures
treatment options
algorithm for, 37t
quality-of-life issues and, 116
Head and neck surgery, fistulae in,
307–319. See also Fistulae,
postoperative
Hearing aids, versus cochlear
implants, 430
Hearing loss
bilateral congenital
following microsurgery for
infracranialicular acoustic
neuroma, 273
following tympanoplasty, 216
sensorineural, otosclerosis and, 233,
234
treatment-related, causes of, 273
unilateral congenital, impact of, 377.
See also Unilateral atretic ear
Hearing status
in aural atresia
long-term, 378t
postoperative, 377t
in infracranialicular acoustic
neuroma, 265
preservation, 270–271
Hematomas, SMAS procedures and,
141145
Herpes simplex infection
acute facial paralysis and, 219–220
after laser skin resurfacing,
159, 172
after phenol peels, 169
after trichloroacetic acid peel, 166
Herpes zoster oticus, 221
Heterologous cartilage grafts, in
rhinoplasty, 184–185
High-resolution computed tomography
in jugular foramen tumor
diagnosis, 459
in unilateral atretic ear evaluation,
382–383, 384
HNSCC. See Head and neck squamous
cell carcinoma
Homologous grafts, in rhinoplasty, 176–177, 184
advantages and disadvantages, 174t
alloplastic implants versus, 173–190
materials for, 175t
Hormonal activity, glomus jugulare
tumors, 439
HRCT. See High-resolution computed
tomography
Humidification, for pediatric chronic
rhinosinusitis, 370
Hyperkinesis, after facial reinnervation,
management of, 133
Hyperpigmentation
after laser skin resurfacing, 171
after phenol peels, 168–169
after trichloroacetic acid peel, 166
Hypertrophic scarring, after
trichloroacetic acid peel, 166
Hypoglossal to facial nerve transfer, for
paralyzed face rehabilitation,
124
advantages and disadvantages, 126t
Hypopharyngeal reconstruction, 81
Hypopigmentation, after laser skin
resurfacing, 172
Iatrogenic trauma, facial paralysis due
to, 229
Imbrication, of SMAS layer, 138
Immune deficiency
chronic rhinosinusitis and, 358
post-tympanostomy otorrhea and,
196
Implants
alloplastic. See Alloplastic implants
cochlear. See Cochlear implants
in congenitally deaf children. See Congenitally deaf children, cochlear implants in
defined, 187
experience with, 188–189
grafts as alternatives to, 190
indications for, 189–190
rationale for using, 189
Incisions
in bineplane facelift, 151
preoperative marking, 150, 150f
in craniocervical approach to jugular
foramen tumors, 442
Induction chemotherapy, for HNSCC,
41–42
in advanced resectable disease, 49–50
in locally advanced disease, 36
Infection
after skin resurfacing. See Herpes
simplex infection
causing acute facial paralysis, 219
in ear, following tympanoplasty, 216
Intra-arterial chemotherapy, for
HNSCC, 45
in advanced resectable disease, 52
Intracanalicular acoustic neuroma,
264–278
characteristics, 265
hearing status in, 265
management options for, 265–268
algorithm, 273, 274f
observation with serial imaging,
268, 277
in patients with hearing loss, 266
in patients with serviceable hearing,
266–267
stereotactic radiosurgery, 267–268,
277
surgical, 265–266, 270–271, 277
symptoms associated with, 276
Intranasal approach, in inverting
papilloma management, 22
Intratemporal injury, facial paralysis due
to, 228–229
decision algorithms, 229t
Intratympanic aminoglycosides, for
Meniere’s disease, 252, 257
advantages and disadvantages,
252–253
technique, 253
Inverting papilloma
characteristics, 25
histological, 22
diagnosis, 22, 26, 29–30
differential diagnosis, 26
epidemiology, 29
etiology, 29
evaluation, 22
historical aspects, 21, 29
incidence, 21
management, 20–32
algorithm for, 31f
endoscopic techniques, 22–23, 25,
26–27, 30
external techniques, 22, 30
intrasal approach, 22, 30
radiation therapy, 27, 30
tumor status in, 30
site of origin, 21, 27
Irrigation, in pediatric chronic
rhinosinusitis
maxillary sinus, 363
saline nasal, 370
Isolated Robin sequence, evaluation of
patient with, 389
Jarsdolfer’ grading system, aural
atresia surgery outcome and,
384, 387
Jejunal autografts, 68, 74
Jowl fat, ptotic, SMAS surgery and, 140
Jugular foramen, anatomy, 435–437,
436f, 449–450
Jugular foramen tumors, 434–461
characteristics, 459
classification, 437–438
clinical presentation, 440, 459
diagnosis, 459–460
glomus. See Glomus jugulare tumors
management, 441, 460–461
meningiomas. See Meningiomas,
jugular foramen
neurogenic, 454–455
paragangliomas of temporal bone. See
Temporal bone paragangliomas
preoperative imaging and testing, 441
radiologic characteristics, 452t
radiotherapy for, 454, 461
schwannomas. See Jugular
schwannomas
signs and symptoms, 449t
surgery for, 441, 453–454, 453f
complications, 445–446
craniof deal approach, 442–445,
442t, 443f–445f
lateral skull base approaches, 449, 450t
outcomes, 445–446, 454, 454t
temporal bone secondary metastasis,
456
types, 449, 449t
Jugular schwannomas, 439–440
classification, 440t
clinical presentation, 440–441
radiologic characteristics, 452t
Kennedy stratification, chronic
rhinosinusitis, 86, 86t, 94, 95t
Labial commissure, in SMAS surgery,
140
Labyrinthectomy, for Meniere’s disease,
253, 257, 261
vestibular nerve section combined
with, 254
Laryngopharyngeal reconstruction, 81
Laser-assisted uvulopalatoplasty, for snoring and sleep apnea, 60
Laser skin resurfacing, 169–172
background to, 157–158
complications, 171–172
costs, 161
facelifting with, 153–154
technique, 154
histologic changes following, 170–171
injury prevention during, 171
intraoperative safety considerations, 158–159
mechanism of action, 159
postoperative care, 171
preoperative considerations, 158–159
results, 159–160
safety and predictability, 171
wavelength selection for, 157–158, 161
Lasers
background to use of, 241
safety considerations, 241–242
eye protection during use of, 158, 172
for skin resurfacing. See Laser skin resurfacing
for stapedotomy, 241–247
advantages of, 242
outcomes, 246
patient selection and evaluation, 242–243
postoperative care, 244
revision surgery, 245–246
technique employed in, 243–244
for uvulopalatoplasty, 60
Latissimus dorsi flap, 75
LAUP. See Laser-assisted uvulopalatoplasty
Lipodissection, in biplane facelift, 150–151
Lower eyelid, ectropion after phenol peels, 169
Lower face dissection, in biplane facelift, 151–152
Lower lip, paralyzed, management of, 129f, 133
Lund-Mackay staging system, chronic rhinosinusitis, 86, 87t–88t, 94, 95t
Magnetic resonance imaging
determining need for elective neck dissection, 6
in jugular foramen tumor diagnosis, 459–460
jugular foramen tumors, 452t
parotid neoplasm, 341, 344–345, 349
in pediatric rhinosinusitis diagnosis, 367
temporal bone malignancies, 280
unknown primary with neck disease, 323, 329, 330, 335–336
Malar fat, SMAS surgery and, 140
Malignancies, of temporal bone, 279–289
Malleus-incus head, in aural atresia surgery, 379
Mandible, retrognathic
airway patency and. See Retrognathia, airway obstruction in traction and, 390–391
Mandibular osteotomy, 63
Mandibular reconstruction, 69, 81–82
flap selection for, 74
Marking, preoperative, for biplane facelift, 150, 150f
Masseter muscle transposition, for paralyzed face rehabilitation, 131
Mastoid opacification, post-tympanostomy otorrhea and, 197
Mastoidectomy, cortical, in Meniere’s disease patients, 262
sham surgery and, 262
Maxillary osteotomy, 63
Maxillary sinus, in pediatric chronic rhinosinusitis, 357
cultures, 361
irrigation, 363
Maxillomandibular surgery, for retrognathic patient, 399
Meatus, in aural atresia surgery, 379–380
Med-El cochlear implant system, 424
Medial maxillectomy, endoscopic, for inverting papilloma, 26–27, 26f, 30
Medical Outcomes Study Short Form-36, 85, 94
application, 96–97
sinusitis health status outcomes, 97f-98f
Meniere’s disease
diagnosis and evaluation, 250, 255–256, 256t
diagnosis, 255
management, 249–263
decision flowchart for, 251f
long-term considerations, 255
medical, 250–253, 256–257
surgical, 253–254, 257
otosclerosis concomitant with, 234
staging, 256, 256t
Meniere’s syndrome, 259
Meningiomas, jugular foramen, 440, 455–456
clinical presentation, 456
diagnosis, 456
management, 456
pathology, 456
Mersilene implants, in rhinoplasty, 185
experience with, 188–189
Metastasis(es)
in head and neck squamous cell carcinoma, 3, 3t
chemotherapy for, 34–35, 35t
management of, 16–17, 16f
risk and tumor thickness relationship, 15–16, 16t
secondary, of temporal bone, 456
Methotrexate, for HNSCC, 40
Microvascular free tissue transfer, for facial reanimation, 129f, 131–132
background to, 134
Microsurgery, for intracanalicular acoustic neuroma, 277
hearing loss following, 273
Microvascular free tissue transfer, 68, 69
Mid-facial degloving, for inverting papilloma management, 26, 30
Middle rear, post-tympanostomy otorrhea and irrigation, 197
operative findings in, 197
Milia, after phenol peels, 169
Modified radical neck dissection, 8–11, 9t–11t
reconstructive surgery and, 77
selective neck dissection versus, 10–11, 10t
Morbidity of elective neck dissection for negative neck, 3, 8
uvulopalatopharyngoplasty-associated, 60
Mouth dryness, following tympanoplasty, 216
MRI. See Magnetic resonance imaging
MRND-III. See Modified radical neck dissection
Multidimensionality, of quality-of-life measures, 117, 121
Multidirectional ultrasonography, determining need for elective neck dissection, 6
Multiply disabled child, cochlear implants in, 431
Muscle transposition, for paralyzed face rehabilitation, 124, 129t, 131
advantages and disadvantages, 126t
background to, 134
as early intervention, 136
Myringotomy background to, 196
indications for, 413, 414t
with pressure equalization tube placement. See Draining pressure equalization tubes
Nasal antral window, for pediatric chronic rhinosinusitis, 363, 371
Nasal obstruction, sleep apnea and, 57
Nasal reconstruction. See Rhinoplasty
Nasopharyngeal airway, in retrognathic patient, 390, 398
with Pierre Robin sequence, 395
Nasopharyngeal cancer, chemotherapy for, 36–37, 44–45
Nasopharyngitis, versus chronic rhinosinusitis, 356–357. See also Pediatric chronic rhinosinusitis
Neck negative. See Negative neck postoperative fistulae in, 307–319. See also Fistulae, postoperative
in SMAS surgery, 140
squamous cell carcinoma. See Head and neck squamous cell carcinoma
metastatic, unknown primary. See Unknown primary with neck disease
Neck disease, unknown primary cancer with. See Unknown primary with neck disease
Neck dissection elective. See Elective neck dissection free flaps and, 77
for metastases from parotid gland, 351
radical, 4
selective, 4
therapeutic, elective neck dissection versus, 3, 4f
Negative neck defined, 2
elective neck dissection for. See Elective neck dissection parotid neoplasm in, 346
therapeutic options for, 2–3
Neoadjuvant chemotherapy, for HNSCC, 41–42
Neocollagen formation, laser skin resurfacing and, 159
Nerve injury, SMAS surgery and, 141, 145
Neural plasticity/reorganization, cochlear implants in, 432
Neural reinnervation procedures, for paralyzed face rehabilitation, 124, 129t, 130–131
advantages and disadvantages, 126t
Neurogenic tumors in jugular foramen clinical presentation, 455
diagnosis, 455
epidemiology, 454
pathology, 454–455
staging, 455, 456t
Neuroma, acoustic intracanalicular. See Intracanalicular acoustic neuroma
NO. See Negative neck postoperative fistulae in
Nontouch technique, in tympanostomy tube insertion, 198
Nucleus cochlear implant systems, 424
Obesity, uvulopalatopharyngoplasty outcomes in, 58
Obstruction
airway, in retrognathia. See Retrognathia, airway obstruction in
osteomeatal complex, role in pediatric chronic rhinosinusitis, 357, 362
Obstructive sleep apnea
CPAP for, 57
laser-assisted uvulopalatoplasty for, 60, 63
management algorithm for, 63
perilymph fistulae recurrence rates in, 296
surgical management, 56–65
uvulopalatopharyngoplasty role in, 63
treatment options, nonsurgical, 62–63
Occult metastases, in head and neck squamous cell carcinoma, 3, 3t
Opportunistic biplane facelift, 149
Optical penetration, in laser skin resurfacing, 161
Oral cavity reconstruction, 80
flap selection for, 73–74
tumors, elective neck dissection for, 7
metastasis management in, 17
Oral commissure, in SMAS surgery, 140
Organ preservation, with induction chemotherapy in HNSCC, 50
Organ-sparing approach, in head and neck cancer patients, 116
Orocutaneous fistulae, 312–313
Oropharynx reconstruction, 80–81
flap selection for, 73–74
tumors, elective neck dissection for, 7
metastasis management in, 17
OSA. See Obstructive sleep apnea
Ossicular chain in aural atresia surgery, 379
lateral, in revision stapes surgery, 246–247
perilymph fistulae and, 301
Ossicular reconstruction, primary versus secondary, in cholesteatoma surgery, 206
Osteocutaneous flaps, 74
Osteomeatal complex, 356, 365
obstructive role in pediatric chronic rhinosinusitis, 357, 362
Osteotomies, maxillary and mandibular, 63
Otitis media acute, 401–402
differential diagnosis, 411t
recurrent, 415, 415t
acute facial paralysis resulting from, 219
classification, 406
diagnosis, 411, 411t
etiology, 411–412
microbiology, 406–407, 411–412
treatment options for, 400–416,
401–402, 412–414, 412t–414t
in acute otitis media, 401–402, 412–414, 412t–414t
 recurrent, 415, 415t
 antibiotic susceptibility and, 411, 412t
 background to, 401
 medical, 407–408
 in otitis media with effusion, 402–404, 414–415, 414t
 surgical, 408
 indications, 413, 414t, 415, 415t
 Otitis media with effusion, 402–404
 differential diagnosis, 411, 411t
 treatment options for, 402–404, 414–415, 414t
 antibiotic susceptibility, 411, 412t
 Otorrhea, following tympanostomy. See Post-tympanostomy otorrhea
 Otosclerosis management, 232–248
 background to, 233, 238
 medical, 236
 patient selection, indications for, 233–234
 surgical. See also Revision surgery, stapedectomy; Stapedectomy
 criteria for, 238
 laser use in, 241–247. See also Lasers, for stapedotomy
 Outcomes assessment after sinus surgery. See Sinus surgery, outcomes in
 in head and neck cancer. See Quality-of-life measures, in head and neck cancer management
 Oval window, otosclerosis management and, 233, 234, 235, 241
 Paclitaxel (Taxol), for HNSCC, 34
 Palatal insufficiency, risk after uvulopalatopharyngoplasty, 58
 Palliative care, for head and neck cancer patients, 116
 Palliative chemotherapy, in HNSCC, 39–41
 Paragangliomas, temporal bone. See Temporal bone parangangliomas
 Paralyzed eye, 123
 Paralyzed face acute. See Acute facial palsy/paralysis following tympanoplasty, 216
 problems associated with, 128, 128t
 rehabilitation, 122–136 after parotidectomy, 129–130, 129t
 background to, 134
eye, 123
 free flap use in, 82, 129t, 131–132, 134
goals, 123–126, 126t
 hyperkinesis and, 133
 lower lip, 129f
 methods, 123–126, 126t. See also Dynamic procedures; Static procedures; individually named procedures
 middle third of face, 128–130, 129f
 strategy for, 135f
 synkinesis and, 133
 upper third of face, 128, 128f
 static reanimation procedures in patient recovered from, 136
 traumatic, 228–230
 Parotid neoplasm, 339–354
 benign, resection extent for, 350
 evaluation and management algorithm for, 342f
 fine-needle aspiration biopsy, 340, 344–345, 348–349
 frozen section use in, 345
 imaging studies, 341, 344–345, 349–350
 facial nerve and management, 350–351
 monitoring, 345
 inoperable, radiotherapy for, 352
 malignant and recurrent, 344
 radiotherapy for, 341–342
 treatment choices for adjunctive therapy, 346–347
 chemotherapy, 346
 radiotherapy, 341–342, 345–346, 351–352
 surgical, 341, 346–347
 benign tumor, 350
 metastatic disease, 351
 Patient empowerment, 108–110, 108t
 Patient expectations, SMAS surgery and, 140
 Patient satisfaction/dissatisfaction, with quality of life, 108–110, 108t
 Pectoralis myocutaneous flap, 73, 75
 Pediatric chronic rhinosinusitis, 355–375
 anatomy, 365
 variations in, 362
 assessment and management steps, 372t
 background to, 356–357
definitions, 366
 problems in, 356–357
diagnosis, 367
 cultures in, 361
 imaging studies in, 361, 367
 embryology, 365
 osteomeatal complex obstruction and, 357, 362
 physiology and pathophysiology, 361–362, 365–366
 predisposing factors in, 357–358, 367–369
 symptoms and signs, 366–367
 treatment options for medical, 359, 362, 369–370, 370t
 Pediatric endoscopic sinus surgery, for pediatric chronic rhinosinusitis, 359, 363, 371–372. See also Functional endoscopic sinus surgery
 assessment, 360
 indications, 371
 problems and complications, 359–360
 Pediatric sinusitis chronic. See Pediatric chronic rhinosinusitis
 conditions mimicking, 358
 diagnosis, 358
 heterogeneity, 357–358
 history, 356
 radiologic evaluation, 358
 Penetrating temporal bone trauma, facial paralysis due to, 229
 Pericranial grafts, in rhinoplasty, 190
 Perilymph fistulae, 290–306
 background to, 291–292, 300–301
 bilateral, 294
 classification, 292t
 clinical presentation, 292–293, 293t, 300, 303–304
 comorbidity, 295–296
 complications, 296
 described, 300
diagnosis, 292–294, 301, 304–305
 experimental observations in, 300–301
 management options conservative, 294, 301
 surgical, 295, 301–302
 transtympanic gentamicin ablation, 294–295
Perilymph fistulae (continued)
- treatment failures in, 295
- pathophysiology, 303
- symptoms, 293
- traumatic, 296
PESS. See Pediatric endoscopic sinus surgery
PET. See Positron emission tomography
PET (pressure equalization tube). See Draining pressure equalization tubes, management
Petrosectomy, posterior, 442–443
Pharyngocutaneous fistulae, 312
Pharyngoesophageal reconstruction, 67–69, 80–81
- flap selection for, 74
Phenol peels, 160, 167–169
- complications, 168–169
- indications for, 167
- mechanism of action, 167
- preparation for, 167
- technique, 167–168
Photoaging, histologic effects, 163–164
Physicians, role in patient’s quality of life, 121
Pierre Robin sequence
- airway management in, 391
- airway obstruction types in, 394
- classification attempts, 394
- evaluation of patient with, 389, 394
- syndromes associated with, 394
Pilots, otosclerosis management in, 234
Platysma, anterior, in biplane facelift, 151
PLFs. See Perilymph fistulae
Plication, of SMAS layer, 138–139
- techniques, 139–140
Plume hazard, during laser skin resurfacing, 158
Polyamide implants, in rhinoplasty, 178–179
Polyester implants, in rhinoplasty, 178
Polystyrene implants, in rhinoplasty, 178
Polysomnography
- in Pierre Robin sequence patient, 394, 395
- in uvulopalatopharyngoplasty candidates, 59–60
Polytetrafluoroethylene implants, in rhinoplasty, 178, 185
Positioning
- for airway management in retrognathic patient, 390, 391, 397
- with Pierre Robin sequence, 395
- for craniocebral approach to jugular foramen tumors, 441, 443
Positron emission tomography
determining need for elective neck dissection, 6–7
parotid neoplasm, 341, 350
unknown primary with neck disease, 323, 329, 330, 335–336
Post-tympanostomy otorrhea
- bacteriology in, 194
- factors related to operative approaches, 197–198
- operative findings, 197
- patient characteristics, 196–197
- postoperative management, 198–200
- granulation tissue and, 200
- incidence and onset, 194
- management strategies, 194–195
- early, 198–199
- later, 199
- prophylactic antibiotics, 198
- topical antibiotics, 199
- minimizing risk for, 200–201
- recidivistic, 200
- swimming and, 199–200
- and tube removal, 200
Posterior petrosectomy, 442–443
Postoperative radiation, after selective neck dissection, 11
Prelingual deafness, cochlear implant performance in children with, 425
Preoperative marking, for biplane facelift, 150, 150f
Pressure equalization tube, draining
management of. See Draining pressure equalization tubes, management
Presumed perilymphatic fistula repair, for Meniere’s disease, 253
Preventive measures, nonsquamous cancer, 52
Prophylactic antibiotics, for tympanostomy tube insertion, 198
Prosthesis, for stapledectomy, 235, 239
Psychotropic drugs, use in Meniere’s disease, 261
PTO. See Post-tympanostomy otorrhea
Ptotic jowl fat, SMAS surgery and, 140
Quality of life, head and neck cancer patients
- assessment instruments for. See Quality-of-life measures definitions, 101–102, 117
- physician’s role in improving, 121
- recommendations for enhancing, 110–113, 110t
Quality-of-life measures
- in head and neck cancer management, 100–121
- background and current status, 103, 105–107
- future directions, 107–108
- multidimensional nature of, 117, 121
- patient satisfaction/dissatisfaction and, 108–110, 108t, 110t
- physician’s role, 120–121
- personal perspective on, 120–121
- rationale for, 101–102
- in rhinoconjunctivitis, 96
- spectrum and characteristics, 102–103, 104t
Radial forearm flap, in reconstructive surgery, 73, 74, 75
osteocutaneous, 74
Radiation therapy
- after selective neck dissection, 11
- for glomus jugulare tumors, 446, 461
- for HNSCC, chemotherapy with, 41.
- See also Concomitant chemo/radiotherapy, for HNSCC
- in locally advanced disease, 36, 37
- for intracanalicular acoustic neuroma.
- See Radiosurgery
- for inverting papilloma, 27, 30
- for parotid neoplasm, 345–346, 351–352
- malignant and recurrent, 341–342
- prior to reconstructive surgery, 76
- quality-of-life issues and, 110
Radical neck dissection, 4
- modified. See Modified radical neck dissection
- Radiofrequency ablation, of soft palate, for snoring, 60
Radiosurgery, for intracanalicular acoustic neuroma, 267–268
development, 271
experience with (University of Pittsburgh), 271–273, 272f
- technique, 271
Ramsey-Hunt syndrome, 221
Reanimation, facial. See Paralyzed face, rehabilitation
Recidivistic otorrhea, following tympanostomy tube insertion, 200
Sinus surgery (continued)
outcomes in, 84–99
evaluation scales, 85
future directions, 90
long-term, 85, 87
management strategies, 88–89, 89f
objective measures, 85, 94–96, 96t
revision surgery and, 89
staging systems, 85, 86, 86t, 87t–88t, 94
subjective measures, 84–85, 94–96, 96t
patient evaluation for, 91
underlying diseases and conditions and, 92

Sinusitis
chronic or recurrent, 92
diseases and conditions associated with, 91–92
invasive fungal, 92
pediatric. See Pediatric sinusitis treatment
algorithm for, 92. See also Sinus surgery outcomes. See Sinus surgery, outcomes in
Skin damage, during laser skin resurfacing, 158
Skin excision, in biplane facelift, 153
Skin resurfacing, 156–172
chemical agents for, 160
histologic effects, 163–164
laser-assisted. See Laser skin resurfacing
mechanical, 160
patient selection for, 164
Skin type
classification
Fitzpatrick, 159t, 164t
Glogau, 165t
resurfacing technique and, 158–159, 164
Skull base
reconstruction, 69
flap selection for, 75
tumors. See Jugular foramen tumors
Sleep apnea. See Obstructive sleep apnea
SMAS. See Subcutaneous musculoaponeurotic system
Smoking, SMAS surgery and, 140
SND. See Selective neck dissection
Snoring
laser-assisted uvulopalatoplasty for, 60
uvulopalatopharyngoplasty for, 56–65
indications for, 60–61
SNOT-20 (Sinonasal Outcome Test), 85, 96
Soft palate, radiofrequency ablation for, 60
Somnoplasty, for snoring, 60
SPECT. See Single positron emission computed tomography
Spirituality, impact on medical outcomes, 109–110
Split thickness skin grafts, for reconstructive surgery, 73, 75
in aural atresia, 379
Squamous cell carcinoma
of head and neck. See Head and neck squamous cell carcinoma
temporal bone, 284–285
clinical and radiographic evaluation, 284–285
clinical manifestations of, 285
diagnosis, 287
epidemiology, 284
treatment, 285, 287–288
unknown primary, metastatic to neck. See Unknown primary with neck disease
Staging
chronic rhinosinusitis, 86, 86t, 87t–88t
in elective neck dissection, 4
neurogenic tumors of jugular foramen, 455
temporal paragangliomas, 451, 451t
in tympanoplasty, 216
Stapedectomy
audiometry during, 235
footplate fenestra in, 235
patient selection criteria for, 233–234, 238
perilymph fistulae and, 300
prosthesis for, 235
revision. See Revision surgery, stapedectomy
surgical algorithm for, 234–235
techniques and outcomes in, 238–239
Stapedotomy
laser use in, 241–247
revision surgery. See Revision surgery, stapedotomy
perilymph fistulae and, 300
Static procedures, for paralyzed face rehabilitation, 129t, 132
advantages and disadvantages of, 126t
background to, 134
in recovered facial palsy patient, 136
in temporalis flap use contraindicated patient, 136
Static suspension, for paralyzed face rehabilitation, 124–125, 132
advantages and disadvantages, 125–126, 126t
benefits, 125
technique, 125
Stereotactic radiosurgery, for intracanalicular acoustic neuroma, 267–268
development, 271
experience with (University of Pittsburgh), 271–273, 272f
technique, 271
Sternocleidomastoid muscle, in craniocervical approach to jugular foramen tumors, 444f
Steroids
for pediatric chronic rhinosinusitis, 369
use in Meniere’s disease, 252, 258, 261
Stickler syndrome, 394, 395
Streptomycin, use in Meniere’s disease, 261
Subcutaneous musculoaponeurotic system layer, 134
described, 138–139, 139f
imbrication, 138
plication, 138–139
Subcutaneous musculoaponeurotic system surgery
background to, 142–143
complications, 140–141, 145
considerations in, 140
versus deep-plane rhytidectomy, 137–155
indications and contraindications for, 146
outcomes, 144–146
techniques, 143–144
plication, 139–140
tuck rates in, 145, 145t
Subglottic cancer, elective neck dissection for, 7
Subcapular system, free flaps from, 75
Sun avoidance, after laser skin resurfacing, 159
Supraglottic cancer
elective neck dissection for, 7
reurrence pattern in, 11, 11t
Surgical lasers. See Lasers
Swimming, after tympanostomy, 199–200
Symmetry, facial, restoration of, 134
Sympathomimetic amines, use in Meniere’s disease, 261
Synkinesis, after facial reinnervation, 133
Taste disturbance, following tympanoplasty, 216
Teflon cup piston prosthesis, for stapedectomy, 239
Temple dissection, in biplane facelift, 151
Temporal bone
penetrating trauma to, facial paralysis and, 229
secondary metastasis to jugular foramen, 456
Temporal bone malignancies, 279–289
clinical manifestations, 285t
diagnosis, 287
differential diagnosis, 284t
epidemiology, 284
evaluation, 280
clinical and radiographic, 284–285
signs and symptoms, 285t
treatment algorithm for, 281
Temporal bone paragangiomas, 450–454
clinical presentation, 451
diagnosis, 451–453, 452t
epidemiology, 450
pathology, 450–451
radiologic characteristics, 452t
staging, 451, 451t
surgical outcomes, 454
Temporalis muscle transposition, for paralyzed face rehabilitation, 124, 131
advantages and disadvantages, 126t
contraindicated, 136
Temporoparietal fascia flap, for facial reanimation, 134
Therapeutic neck dissection, elective neck dissection versus, 3, 4f, 7–8
Thermal transmission, in laser skin resurfacing, 161
Tinnitus
following tympanoplasty, 216
perilymph fistulae and, 304
Tissue grafts, otosclerosis management and, 235
Tissue vaporization, sequence of events in, 161
TND (therapeutic neck dissection), 3, 4f, 7–8
Tongue-lip adhesion, in retrognathic patient, 390, 391
with Pierre Robin sequence, 395
Tongue position, posterior, and airway patency in retrognathia. See retrognathia, airway obstruction in
Tonsillar hypertrophy, sleep apnea and, 57
Tonsillectomy, in search for primary cancer of upper aerodigestive tract, 336
Toxicity, phenol peels, 168
Tracheoesophageal puncture, 74
Tracheotomy, in retrognathic patients, 397
with Pierre Robin sequence, 395
Transcanal labyrinthectomy, for Meniere’s disease, 253
Transmastoid labyrinthectomy, for Meniere’s disease, 253, 257
Trapezius muscle, in selective neck dissection, 8
Traumatic face paralysis, 228–230
closed-head, 228–229, 229t
facial nerve repair and, 230
iatrogenic, 230
penetrating, to temporal bone, 229
Treacher Collins syndrome, 394
Trichloroacetic acid peels, 160
complications, 166
indications for, 165–166
postpeel care, 166
pretreatment, 166
technique, 166
Tumors, jugular foramen. See Jugular foramen tumors
Tympanic membrane, in aural atresia surgery, 379
Tympanocentesis, indications for, 413, 414t
Tympanoplasty, for cholesteatoma, risks and complications, 216
Tympanostomy
vent tube insertion and. See also Draining pressure equalization tubes complication following. See Post-tympanostomy otorrhea indications for, 415, 415t
and removal, 200
water precautions after, 199–200
Ultrasonography
multidirectional, determining need for elective neck dissection, 6
parotid neoplasm, 349–350
Unilateral cutaneous car, 376–387
embryology, 381–382, 386
epidemiology, 386
evaluation of patient with, 382
and hearing restoration, probability and stability, 377–378, 377t, 378t
impact of, 377
radiologic evaluation, 382–383
surgical treatment approaches and techniques in, 379–380, 383, 386
care following, 383–384
in children, 384
complications, 384
evolution, 384
indications, 384, 386–387
patient selection for, 378–379
procedures, 384
risks, 378, 387
timing, 383
Unknown primary with neck disease
assessment and management, 320–338
endoscopy in, 324
histopathologic diagnosis, 329–330
imaging studies in, 323, 329, 330, 335–336
node location in, 322–323
outcome, 333
prognosis, 326
treatment, 324–326, 331–333, 336–337
Upper aerodigestive tract
cancer of. See Unknown primary with neck disease
fistulae formation during surgery in, 307–319
Uvulopalatopharyngoplasty
history of, 59
morbidity associated with, 60
palatal insufficiency associated with, 58
patient selection for, 59
for snoring and sleep apnea, 56–65
<table>
<thead>
<tr>
<th>term</th>
<th>page numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaporization, in laser-assisted skin resurfacing</td>
<td>161</td>
</tr>
<tr>
<td>Vasodilator therapy, for Meniere’s disease</td>
<td>257</td>
</tr>
<tr>
<td>Velocardiofacial syndrome</td>
<td>394</td>
</tr>
<tr>
<td>Vent tubes. See Draining pressure equalization tubes</td>
<td></td>
</tr>
<tr>
<td>Vertigo in Meniere’s patient episodic</td>
<td>257</td>
</tr>
<tr>
<td>treatment, 259–262, 260f</td>
<td></td>
</tr>
<tr>
<td>medical, 259–261, 260f</td>
<td></td>
</tr>
<tr>
<td>surgical, 261–262</td>
<td></td>
</tr>
<tr>
<td>perilymph fistulae and, 295–296, 304</td>
<td></td>
</tr>
<tr>
<td>Vestibular function tests, in perilymph fistulae diagnosis</td>
<td>304</td>
</tr>
<tr>
<td>Vestibular nerve section, for Meniere’s disease</td>
<td>254, 257</td>
</tr>
<tr>
<td>combined with labyrinthectomy, 254</td>
<td></td>
</tr>
<tr>
<td>translabyrinthine, 261</td>
<td></td>
</tr>
<tr>
<td>Vestibular schwannoma, intracanalicular growth of. See Intracanalicular acoustic neuroma</td>
<td></td>
</tr>
<tr>
<td>Viral infections acute facial paralysis and, 219–220</td>
<td></td>
</tr>
<tr>
<td>after laser skin resurfacing, 159, 172</td>
<td></td>
</tr>
<tr>
<td>after phenol peels, 169</td>
<td></td>
</tr>
<tr>
<td>after trichloroacetic acid peel, 166</td>
<td></td>
</tr>
<tr>
<td>in unknown primary with neck disease, 329, 330–331</td>
<td></td>
</tr>
<tr>
<td>Water precautions, after tympanostomy</td>
<td>199–200</td>
</tr>
<tr>
<td>Wound care, after laser skin resurfacing</td>
<td>171</td>
</tr>
<tr>
<td>Wound closure in biplane facelift</td>
<td>153</td>
</tr>
<tr>
<td>in craniocervical approach to jugular foramen tumors, 445, 445f</td>
<td></td>
</tr>
<tr>
<td>Wound complications in aural atresia surgery</td>
<td>384</td>
</tr>
<tr>
<td>in reconstructive surgery</td>
<td>76</td>
</tr>
<tr>
<td>Xenografts, in rhinoplasty</td>
<td>184–185</td>
</tr>
<tr>
<td>Zyplast, for rhinoplasty</td>
<td>184</td>
</tr>
</tbody>
</table>